These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 3901243)
1. The chemokinetic inhibitory factor (CIF) in serum of CLL patients: correlation with infection propensity and disease activity. Siegbahn A; Simonsson B; Venge P Scand J Haematol; 1985 Jul; 35(1):80-7. PubMed ID: 3901243 [TBL] [Abstract][Full Text] [Related]
2. Production of chemokinetic inhibitory factor (CIF) by normal blood and spleen B lymphocytes. Siegbahn A; Rosén A; Venge P; Aman P; Nilsson K Leuk Res; 1986; 10(2):179-86. PubMed ID: 3485223 [TBL] [Abstract][Full Text] [Related]
3. The chemokinetic inhibitory factor derived from chronic lymphocytic leukaemia cells. Partial purification and characterization of a new lymphokine. Siegbahn A; Nilsson K; Venge P Scand J Immunol; 1986 Jan; 23(1):15-23. PubMed ID: 3704559 [TBL] [Abstract][Full Text] [Related]
4. Specific binding of B-CLL cell-derived chemokinetic inhibitory factor (CIF) to human polymorphonuclear leukocytes. Siegbahn A; Garcia RC; Kishi K; Nilsson K; Venge P Eur J Haematol; 1987 Aug; 39(2):172-9. PubMed ID: 3666104 [TBL] [Abstract][Full Text] [Related]
5. Identification of a chemokinetic inhibitor in serum from patients with chronic lymphocytic leukaemia. Siegbahn A; Venge P; Nilsson K; Simonson B Scand J Haematol; 1982 Feb; 28(2):122-31. PubMed ID: 7046030 [TBL] [Abstract][Full Text] [Related]
7. Cellular origin of the chemokinetic inhibitor of polymorphononuclear leucocytes found in sera from patients with chronic lymphocytic leukaemia. Siegbahn A; Venge P; Nilsson K Scand J Haematol; 1983 Aug; 31(2):184-92. PubMed ID: 6310732 [TBL] [Abstract][Full Text] [Related]
8. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616 [TBL] [Abstract][Full Text] [Related]
9. Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels. Rivkina A; Vitols G; Murovska M; Lejniece S Exp Oncol; 2011 Jun; 33(2):99-103. PubMed ID: 21716207 [TBL] [Abstract][Full Text] [Related]
10. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Molica S; Vitelli G; Levato D; Gandolfo GM; Liso V Br J Haematol; 1999 Dec; 107(3):605-10. PubMed ID: 10583266 [TBL] [Abstract][Full Text] [Related]
12. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957 [TBL] [Abstract][Full Text] [Related]
13. Serum inhibitory factor for guinea pig macrophage and neutrophil chemotaxis found in cancer patients. Miyahara T; Torisu M Gan; 1981 Dec; 72(6):854-61. PubMed ID: 7341335 [TBL] [Abstract][Full Text] [Related]